Navigation Links
Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer

ASCO Oral Presentation Reports Significantly More Patients Treated with Taxotere(R)-Based Chemotherapy Regimen Survived at Least Three Years

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Taxotere(R) (docetaxel) Injection Concentrate-based chemotherapy (Taxotere plus prednisone) maintained long-term efficacy as a treatment for advanced (metastatic) hormone-resistant prostate cancer patients, according to the three-year updated results of the landmark TAX 327 study. Results of the international multi-center phase III trial were reported in an oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

The TAX 327 data show that among patients with metastatic hormone- resistant prostate cancer, significantly more of those treated with Taxotere(R) 75mg/m2 combined with prednisone 5 mg once every three weeks survived at least three years, than those treated with anti-cancer antibiotic mitoxantrone combined with prednisone. Patients treated with the Taxotere(R) regimen lived a median of three months longer (19.3 months versus 16.3 months, p=0.006) and had a 21% lower risk of dying (HR=17.6-21.3). These results are consistent with results published in 2004 in the New England Journal of Medicine and document the maintenance of the survival benefit previously reported in patients treated with the Taxotere-based therapy.

"The results confirm docetaxel's survival benefit in patients with metastatic hormone resistant prostate cancer," said study author Dominik R. Berthold, Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada. "Prolonged survival is extremely important for these patients and docetaxel is the only chemotherapeutic agent to demonstrate a survival benefit in this setting."

Original TAX 327 Analysis Showed Improved Survival

The TAX 327 study was initiated in 2000 to evaluate long-term survival among men with metastatic h
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
3. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:12/2/2008)...e/ -- Researchers using functional,MRI (fMRI) hav... brain,responsible for suppressing memory is dysf...ed psychiatric disorders. Results of the study wil... Radiological Society of North America,(RSNA). ,...er stress-related disorders,traumatic memories a...
(Date:12/2/2008)...IBT Laboratories, a leading clinical-diagnostics ... immunology and allergy assays, announced that it ...of patients whose immune systems may be compromise...otherapy drugs, or because they are taking immuno-...lant. The company launched the two new assays, the...
(Date:12/2/2008)...stCall/ -- Micromet, Inc. (Nasdaq: MITI ), a bio...ry antibodies for the treatment of cancer, inflamm...t it has entered into an agreement expanding its C...gsbridge Capital Limited, a private investment gro... has committed to provide up to $75 million of cap...
(Date:12/1/2008)...rstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: ... the world,s leading medical journals, results of ...experimental compound tasimelteon (VEC-162). The ...latonin agonist tasimelteon (VEC-162) for transien...controlled multicentre trials." Results are report...
Breaking Medicine Technology:Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Stomach ulcer bug causes bad breath 5990 1Stomach ulcer bug causes bad breath 5990 2Ultrasound waves aid in rapid treatment of DVT 30399 1Ultrasound waves aid in rapid treatment of DVT 30399 2Scripps research team defines new painkilling chemical pathway 5988 1Scripps research team defines new painkilling chemical pathway 5988 2AirMed International wins Air Ambulance of the Year for Second Consecutive Year 30392 1AirMed International wins Air Ambulance of the Year for Second Consecutive Year 30392 2
(Date:12/3/2008)...e/ -- MedQuist Inc. (Nasdaq: MEDQ ), the largest... in the world, is pleased to announce the positive... , Resolution of the DOJ Investigation , ...d an administrative HIPAA subpoena for documents f...) on December 17, 2004. The subpoena sought inform...
(Date:12/3/2008)...c study found that patients with low-grade gliomas...urgeries to successfully remove the entire tumor. ...le, patients survived significantly longer when su...y is available online as an advance publication in...nals.org/cgi/content/abstract/15228517-2008-102v1 ...
(Date:12/3/2008)...e/ -- The American College of Surgeons (ACS) today...s committee report on resident duty hours that was...e on Optimizing Graduate Medical Trainee (Resident...ty. , , ACS agrees with the IOM in its co...0-hour work week (averaged over four weeks) are no...
(Date:12/3/2008)...ora Health Care,s Women,s Pavilion,( http://www.a...Salon and Spa of,New Berlin partnered for a new k...ink hair extensions. , Throughout the month...for,$15 each at the Aurora Women,s Pavilion in We... Spa in New Berlin. The profits from these bright ...
Breaking Medicine News(10 mins):Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6Health News:Mayo Clinic identifies best treatments for long-term survival in brain tumor patients 2Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2
...vidence that sage can significantly improve memory...might be the key to treating Alzheimer's disease. ...volunteers between ages 18 and 37. Some were given...n placebos. In a word recall test, those who took ...
...s is better at reducing problems in heart transpla...Specifically the drug reduced the incidence of a s...e graft known as coronary vasculopathy.// Previous...ed with another drug reduced the rejection and ris...
...re more vulnerable to serious brain injuries when ...abuse investigators distinguish between accidental...ylvania study found that rotational forces generat...face can cause widespread, potentially serious bra...
... increasingly common procedure for hard-to-treat c...But it can take months or even years for stem cell...he patient is at risk for serious infection. Now, ...one step further with incredible results. Ed Baute...
Other Medicine News:
...ex® Thermovent® T helps provide protection.... It is small and extremely lightweight making it ... With a high rate of heat and moisture recovery, i...tention., ,All HMEs and filters have ISO standard...
...ex® Thermovent® T helps provide protection.... It is small and extremely lightweight making it ... With a high rate of heat and moisture recovery, i...tention., ,All HMEs and filters have ISO standard...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines
Medicine Products: